SP1 and plasma cell myeloma: A wide range of concentrations of mithramycin A (10 nM–1 μM) have been used to inhibit the transcriptional factor activity of Sp1 in various types of cells, including human bronchial epithelial cells, multiple myeloma cells [29], [30], and mouse endothelial cells [25].